# A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients

> **NCT01672762** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 174 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** ipragliflozin

## Key facts

- **NCT ID:** NCT01672762
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-25
- **Primary completion:** 2013-04-13
- **Final completion:** 2013-04-13
- **Target enrollment:** 174 (ACTUAL)
- **Last updated:** 2024-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01672762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01672762, "A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01672762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*